Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.
Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.
Company Details
- Employees
- 14
- Founded
- -
- Address
- Yalelaan 62, Lsi Rooms 1.01-1.07,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- sapreme-technologies.com
- HQ
- Utrecht
Sapreme Technologies Bv Questions
Sapreme Technologies Bv's website is sapreme-technologies.com
Sapreme Technologies Bv's LinkedIn profile is https://nl.linkedin.com/company/sapreme-technologies-bv
Sapreme Technologies Bv has
14 employees.
View email and phone details for 14
employees at Sapreme Technologies Bv.
Sapreme Technologies Bv's industry is
Biotechnology Research
Sapreme Technologies Bv's top competitors are
Radicle Crops,
Bimini Biotech,
Kling Biotherapeutics,
Lava Therapeutics N.v.,
Scellgen,
Multifund,
Bbb Therapeutics,
Bugsee,
Modra Pharmaceuticals,
Nanocell Therapeutics.
Sapreme Technologies Bv's categories are Biotechnology Research
Sapreme Technologies Bv's founding year is 2016
